Pfizer LimitedPFIZERCorporate

Healthcare Drug Manufacturers - General Latest results: Jun 2026 14 quarters of data

₹3,814.00

MCap ₹17,448 Cr · P/E 23.7

Pfizer Limited — Stock analysis & AI research Pfizer Limited — Multibagger AI analysis Pfizer Limited — Seasonality — best & worst months Pfizer Limited — Technical indicators & charts Pfizer Limited — Technical setup — score, trend, support & resistance Pfizer Limited — Falling Wedge pattern forming Pfizer Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 Stocks Cheaper Than Their Industry 📋 Low Debt Stocks 📋 Small Cap Stocks List 📈 SuperTrend Bullish Signal 📈 Lowest Technical Score 📈 Multi-Timeframe Bearish Stocks 📈 Stocks Near 52-Week Low ⚖️ vs Abbott India ⚖️ vs GlaxoSmithKline Pharmaceuticals 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹653 Cr

Sales · Jun 2026

+8.3% YoY

₹248 Cr

Operating Profit · Jun 2026

+18.1% YoY

38.0%

OPM % · Jun 2026

+9.2% YoY

₹204 Cr

Net Profit · Jun 2026

+6.2% YoY

₹44.70

EPS · Jun 2026

+6.7% YoY

📝 Pfizer Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Pfizer Limited reported revenue of ₹653 crore for the quarter ended June 2026 (Q1 FY27), up 8.3% from ₹603 crore in the same quarter last year, and up 3.8% sequentially over the March 2026 quarter.

Net profit rose 6.2% year-on-year to ₹204 crore, from ₹192 crore. Earnings per share (EPS) came in at ₹44.70.

Operating profit stood at ₹248 crore — an operating margin (OPM) of 38.0%, compared with 34.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Pfizer Limited posted revenue of ₹2,519 crore, a growth of 10.4% over FY25, with a net profit of ₹723 crore (down 5.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,569 crore with a net profit of ₹735 crore.

Valuation snapshot

At the current price of ₹3,814.00, PFIZER has a market capitalisation of ₹17,448 crore and a trailing P/E of about 23.7.

Within the Drug Manufacturers - General industry, it is the 3rd-largest of the 5 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 63.92%, foreign institutional investors (FIIs) 1.63%, domestic institutional investors (DIIs) 17.52%, public shareholders 16.92% of Pfizer Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹17,448 Cr

Current Price ?

₹3,814.0

P/E ?

23.74below ind

Industry P/E ?

62.30

P/B ?

4.15

P/S ?

6.79

P/FCF ?

18.48

Enterprise Value ?

₹17,518 Cr

EV/EBITDA ?

18.60

PEG ?

2.97

Earnings Yield ?

5.1%

Dividend Yield ?

1.97%

Profitability & Returns

Sales (TTM) ?

₹2,569 Cr

OPM ?

36.7%

Profit after tax (TTM) ?

₹735 Cr

EPS (TTM) ?

₹160.66

ROCE ?

24.0%

ROE ?

17.5%

ROA ?

14.9%

Growth

Sales — latest qtr ?

₹653 Cr

PAT — latest qtr ?

₹204 Cr

YoY qtr sales growth ?

8.3%

YoY qtr profit growth ?

6.2%

Sales growth (3y) ?

Sales growth (5y) ?

Profit growth (3y) ?

Profit growth (5y) ?

Financial Health

Debt ?

₹70 Cr

Debt to Equity ?

0.02

Interest Coverage ?

94.1

Current Ratio ?

N/A

Ownership

Promoter holding ?

63.92%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-16.5%

Return 6 months ?

-23.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	573	531	575	540	547	563	589	538	592	603	642	645	629	653	+8.3%	+3.8%
Operating Profit	182	111	183	153	189	177	189	146	228	210	230	228	236	248	+18.1%	+5.1%
Other Income	12	33	36	44	75	42	43	43	217	67	42	-20	50	45	-32.8%	-10.0%
Interest	3	3	3	3	7	2	2	2	3	3	2	2	2	1	-66.7%	-50.0%
Depreciation	26	16	15	18	14	15	15	15	16	14	14	14	15	14	+0.0%	-6.7%
Profit Before Tax	165	126	201	176	244	203	215	172	426	260	255	192	269	277	+6.5%	+3.0%
Net Profit	130	94	149	130	179	151	158	128	331	192	189	142	200	204	+6.2%	+2.0%
EPS	28.34	20.44	32.56	28.41	39.10	32.94	34.61	27.89	72.34	41.91	41.32	31.00	43.68	44.70	+6.7%	+2.3%
OPM %	31.8%	20.9%	31.8%	28.3%	34.6%	31.4%	32.1%	27.1%	38.5%	34.8%	35.8%	35.3%	37.5%	38.0%	+9.2%	+1.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹2,282 Cr	₹2,519 Cr	₹2,569 Cr	+10.4%
Operating Profit	₹740 Cr	₹904 Cr	₹942 Cr	+22.2%
OPM %	32.43%	35.89%	36.67%	+10.7%
NPM %	33.64%	28.70%	28.61%	-14.7%
Other Income	₹345 Cr	₹139 Cr	₹117 Cr	-59.7%
Depreciation	₹61 Cr	₹57 Cr	₹57 Cr	-6.2%
Interest	₹9 Cr	₹9 Cr	₹7 Cr	+5.8%
EBIT	₹679 Cr	₹847 Cr	₹885 Cr	+24.7%
PBT	₹1,016 Cr	₹976 Cr	₹993 Cr	-4.0%
Tax	₹45 Cr	—	—	—
Net Profit	₹768 Cr	₹723 Cr	₹735 Cr	-5.8%
EPS	₹167.78	₹157.91	₹160.70	-5.9%
Material Cost	₹172 Cr	—	—	—
Employee Cost	₹96 Cr	—	—	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	46	46	46	46	+0.0%
Reserves	3,162	3,550	4,172	4,157	-0.4%
Borrowings	41	40	41	70	+70.7%
Other Liabilities	752	593	653	649	-0.6%
Total Liabilities	4,001	4,229	4,911	4,922	+0.2%
Fixed Assets	749	713	724	678	-6.4%
CWIP	8	0	8	20	+150.0%
Investments	0	0	0	0	—
Other Assets	3,244	3,516	4,180	4,224	+1.1%
Total Assets	4,001	4,229	4,911	4,922	+0.2%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	356	257	660	968	+46.7%
Cash from Investing Activity	-36	54	-71	-562	-691.5%
Cash from Financing Activity	-346	-235	-205	-798	-289.3%
Net Cash Flow	-26	75	383	-392	-202.3%
Free Cash Flow	292	291	783	944	+20.6%
CFO/OP	81%	64%	110%	105%	-4.5%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	23	31	31	26	-16.1%
Inventory Days	175	200	214	195	-8.9%
Days Payable	91	77	68	89	+30.9%
Cash Conversion Cycle	107	154	177	132	-25.4%
Working Capital Days	1	24	23	9	-60.9%
ROCE %	26%	22%	22%	24%	+9.1%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	63.92%	63.92%	63.92%	63.92%	63.92%	+0.0%
FIIs	2.40%	2.60%	2.71%	2.81%	1.63%	-42.0%
DIIs	17.23%	17.11%	17.05%	16.89%	17.52%	+3.7%
Public	16.45%	16.37%	16.32%	16.36%	16.92%	+3.4%
No. of Shareholders	1,03,222	1,03,480	1,00,933	99,545	1,04,472	+4.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	GLAXO GlaxoSmithKline Pharmaceuticals	₹2,818.90	47,754	44.7	3,955	1,068	40.8%	27.0%	1.9%	11.6%	16.6%	15.7%
2	RUBICON RUBICON RESEARCH	₹1,839.40	30,367	103.7	1,936	288	23.3%	14.9%	—	—	51.8%	97.2%
3	PFIZER Pfizer	₹4,055.00	18,551	25.2	2,569	735	36.7%	28.6%	10.4%	-5.8%	8.3%	6.2%
4	SAIPARENT Sai Parenterals	₹498.00	2,200	—	—	—	—	—	—	—	435.1%	458.0%
5	SYMBIOTEC Symbiotec Pharmalab	₹1,107.00	—	—	—	—	—	—	—	—	7.5%	-53.1%

❓ Frequently asked questions

What was Pfizer Limited's revenue in Q1 FY27?

What was Pfizer Limited's net profit in Q1 FY27?